RxDoctor Payments Data

Jessica Borowicz, DO

Dermatology · Glenview, ILNPI 1477701357

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $62,493 of the $91,080 with a category attached, or 68.6%. 37 manufacturers reported payments, led by Galderma Laboratories, L.p. at 32.6% of the total. Reporting peaked in 2019 at $39,362 and has fallen 92.5% since, to $2,952 in 2025. Among dermatology clinicians in IL with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$91,080in general payments, 2019–2025

Across 967 payments — averaging $94.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Galderma Laboratories, L.p.$30K
  • Bristol Myers Squibb$27K
  • Amgen$19K
  • AbbVie$3K
  • Johnson & Johnson$2K
  • Novartis$2K
  • plus $9K from 31 others

What the payments were for

  • Consulting fees$5,6266%
  • Speaking & faculty fees$62,49369%
  • Travel & lodging$3,5394%
  • Food & beverage$18,62520%
  • Education$7961%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$91,080 in reported general payments places this provider in the 90th percentile of 606 dermatology providers in Illinois.

See all dermatology providers in Illinois

Medicare billing

Part B allowed, 2024
$365,432
Medicare patients
780
Services billed
6,422

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cosentyx Sensoready (2 Pens)Secukinumab15$113,969
SotyktuDeucravacitinib12$78,888
OtezlaApremilast16$78,864
Dupixent PenDupilumab17$67,427
Dupixent SyringeDupilumab11$43,115
Ketoconazole149$2,476
Clobetasol Propionate53$2,333
Metronidazole44$2,030
AmnesteemIsotretinoin12$1,912
Triamcinolone Acetonide183$1,423
Mometasone Furoate49$1,175
Clindamycin Phosphate32$850
Doxycycline Hyclate50$700
Mupirocin54$454
Nystatin22$450

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
E.r. Squibb & Sons, L.L.C.Sotyktu$543$78,88812 claims
AmgenOtezla$18,836$78,86416 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 606 dermatology providers in Illinois.

Other dermatology in Glenview

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →